logo-loader

Alnylam Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$9.43 billion
Price
84.78 USD
Change
3.54%
52 weeks high
96.08
52 weeks low
60.28

In brief

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection.